FDA Grants Fast Track to CytomX's Varseta-M for Colorectal Cancer
CTMX sits 83% above its 52-week low of $1.9.
Summary
The FDA granted Fast Track Designation to Varseta-M for relapsed/refractory metastatic colorectal cancer, a regulatory milestone that can expedite development and review. This follows encouraging Phase 1 data and completed enrollment in the 113-patient monotherapy trial reported earlier this month. The designation supports a planned registrational study in the first half of 2027, a key step toward potential approval. For a clinical-stage biotech with a $723M market cap, this de-risks the program and may attract partnership interest. Watch for the registrational trial design and any additional data updates by end-2026.
At the time of this announcement, CTMX was trading at $3.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $723.4M. The 52-week trading range was $1.90 to $8.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.